Chymotrypsin-Trypsin and Hypomenorrhea

What is Chymotrypsin-Trypsin?

• Breaks down inflammatory proteins and fibrin at sites of injury
• Reduces edema, swelling, and pain
• Has mild fibrinolytic activity (breaks down fibrin clots)
• Enhances local blood flow to injured/inflamed tissue

What is Hypomenorrhea?

Effect of Trypsin-Chymotrypsin on Hypomenorrhea

1. Fibrinolytic action: These enzymes break down fibrin and intracavitary clots/adhesions. In conditions like mild Asherman's syndrome (intrauterine adhesions causing scanty flow), fibrinolytic enzymes can help dissolve the fibrinous adhesions, thereby restoring normal menstrual outflow.
2. Anti-inflammatory effect: By reducing pericervical or endometrial inflammation, they may restore normal endometrial shedding.
3. Anticoagulant potentiation: Trypsin-chymotrypsin has a mild blood-thinning effect. If taken with anticoagulants (warfarin, heparin, clopidogrel), bleeding risk - including menstrual bleeding - increases significantly.

Practical/Clinical Context

Key Point for Pharmacology/Exam Context

Trypsin-Chymotrypsin, due to its fibrinolytic and proteolytic activity, can INCREASE menstrual flow - i.e., it is beneficial in hypomenorrhea caused by fibrinous intrauterine adhesions or obstructed outflow.

Clinical Scenario Analysis: Endometriosis + FET with Incomplete Shedding (Day 2: 8mm)

Understanding the Problem

• Endometriosis (known)
• Hypomenorrhea - very light, painful periods this cycle
• Incomplete endometrial shedding - the old endometrium has not shed properly
• Day 2 baseline ultrasound: 8 mm endometrial thickness - this is a RED FLAG

Why Is This Happening in Endometriosis?

1. Impaired decidualization - the endometrium does not prepare and shed normally
2. Chronic inflammation - altered prostaglandin balance, excess inflammatory cytokines
3. Retrograde menstruation tendency - outflow obstruction or cramping that prevents proper shedding
4. Adenomyosis co-existence - very common with endometriosis, thickens the junctional zone
5. Altered uterine contractility - can prevent complete expulsion of the endometrium

Can Trypsin-Chymotrypsin Help Shed 4-5 mm?

Should This FET Cycle Proceed?

• The new endometrium will be building on top of old, incompletely shed tissue
• This creates a disorganized, non-receptive endometrium
• Implantation failure risk is significantly increased
• There is a risk of building an echogenically inhomogeneous endometrium

What Should Actually Be Done - Clinical Options

• Allow a proper natural bleed, confirm complete shedding next cycle
• Re-scan Day 2 of next cycle - if baseline ≤5 mm, proceed

• Misoprostol (prostaglandin E1 analogue) - can help with uterine contraction and expulsion of remaining endometrium
• Mifepristone - progesterone antagonist that triggers endometrial shedding (used off-label)
• Norethisterone withdrawal - give norethisterone for 5 days, then stop; withdrawal bleed is usually heavier and more complete
• Combined oral contraceptive pill withdrawal bleed - similar principle

• If cycles are repeatedly incomplete, consider GnRH agonist pre-treatment (3-6 months) before FET - this suppresses endometriosis, allows the endometrium to reset, and significantly improves implantation rates in endometriosis patients
• Natural cycle FET (rather than artificial/HRT cycle) is preferred in endometriosis patients - recent evidence shows artificial-cycle FET in endometriosis carries higher obstetric risks

• There is very limited data on proceeding with 8 mm baseline
• Some protocols will attempt if endometrium looks homogeneous and grows normally
• But in endometriosis, the existing endometrium is likely dysfunctional regardless of thickness

Practical Recommendation for This Patient

Do NOT proceed with FET this cycle. The 8 mm Day 2 endometrium is a contraindication to proceeding. Continuing estrogen priming on top of an incompletely shed 8 mm endometrium will produce a thick but potentially non-receptive lining.

1. Cancel this FET cycle
2. Address the incomplete shedding - consider misoprostol or a progestogen withdrawal bleed
3. Evaluate for adenomyosis (3D ultrasound or MRI) - very commonly co-exists with endometriosis and is a frequent cause of incomplete shedding
4. Consider GnRH agonist downregulation for 1-3 months before the next FET attempt
5. When ready to retry - confirm Day 2 baseline ≤5 mm before starting

What Happens When Leuprolide 3.75 mg is Given 1 Week Before Period?

Pharmacology of Leuprolide (GnRH Agonist) - Timeline

Phase 1: FLARE Effect (Days 1-7 after injection)

• Leuprolide initially acts as a GnRH agonist - it stimulates pituitary receptors
• Causes a sudden surge of FSH and LH from the pituitary
• Results in a transient rise in estrogen and progesterone
• Clinical effects: worsening of symptoms temporarily, breast tenderness, possible spotting or light bleeding
• This is why the period is scant/painful this cycle - the endometrium is being influenced by this flare

• Pain (temporary hormone surge worsening endometriosis)
• Very light/incomplete shedding (the elevated hormones from flare are partially supporting the endometrium)

Phase 2: DOWNREGULATION (Weeks 2-4 after injection)

• The pituitary GnRH receptors become desensitized and depleted (downregulated)
• FSH and LH levels fall dramatically
• Estrogen drops to post-menopausal levels (~20-30 pg/mL)
• Ovaries become quiescent - no follicular activity
• Endometrium becomes thin and atrophic (drops to 3-4 mm)
• This typically takes 2-4 weeks after the flare

Phase 3: QUIESCENCE - Confirmed Suppression

• Patient will have a withdrawal bleed (usually within 1-2 weeks of injection as hormones drop)
• After that bleed, the endometrium becomes thin and inactive
• The clinic confirms suppression with:
  • Ultrasound: thin endometrium (<5 mm), no follicles >10 mm
  • Blood test: estradiol <50 pg/mL (ideally <30)

How This Changes the Previous Scenario

What to Expect and When to Start FET

Day 21 of cycle → Leuprolide 3.75 mg injection
   ↓
Days 22-28 → Flare (symptoms may worsen temporarily)
   ↓
Day 28-35 → Withdrawal bleed (usually lighter/shorter than normal period)
   ↓
Day 14-21 of next cycle → Confirm suppression (scan + E2 level)
   ↓
If suppressed → Start oral estradiol (E2 valerate 2 mg/day, increasing)
   ↓
Day 12-14 of estrogen priming → Check endometrial thickness
   Target: ≥7-8 mm, trilaminar pattern
   ↓
Add progesterone → FET on Day 5 of progesterone (for Day 5 blastocyst)

Key Clinical Points for This Patient

1. The incomplete shedding and light painful period this cycle is EXPECTED - it is the flare effect of leuprolide, not a complication
2. Do not attempt FET this cycle - the endometrium is not reliable during the flare phase
3. The withdrawal bleed that follows will likely still be light - this is fine because the purpose is just to allow the endometrium to shed before estrogen priming begins
4. After the withdrawal bleed, start estradiol supplementation once suppression is confirmed
5. For endometriosis specifically - leuprolide pre-treatment is beneficial because it suppresses endometriotic lesions, reduces inflammation, and improves endometrial receptivity before FET
6. The previous 8 mm Day 2 endometrium issue will resolve on its own - after the leuprolide withdrawal bleed and subsequent estrogen priming on a suppressed endometrium, you will build a fresh, synchronous lining

Important Warning

• Increased pelvic pain is expected and temporary
• NSAIDs (ibuprofen, naproxen) can help manage pain during this phase
• Symptoms will improve significantly once downregulation establishes (Week 2-4)

Withdrawal Bleed is Light + Endometrium Still 8 mm - What Now?

Why This Happens After Leuprolide

• Adenomyosis component
• Chronic endometrial inflammation
• Impaired decidualization

The Critical Question: Can You Start Estradiol on Top of 8 mm Baseline?

• Endometrial thickness ≤5 mm (most protocols require <5 mm)
• Estradiol (E2) <50 pg/mL (confirms ovarian quiescence)
• No follicles >10 mm on ultrasound

Step-by-Step Management - What to Actually Do

Step 1: Confirm Suppression First

• If E2 is low (<30-50 pg/mL) - ovaries ARE suppressed by leuprolide ✓
• No follicles on scan ✓
• This confirms the 8 mm is residual endometrium, not new growth from active ovarian estrogen

Step 2: Wait and Re-scan (Most Preferred Approach)

• Wait 7-10 more days and repeat the scan
• With leuprolide suppression established and E2 low, the endometrium often continues to thin gradually even after the main withdrawal bleed
• The residual tissue dries and atrophies because there is no estrogen support
• Many patients go from 8 mm to 4-5 mm within 1-2 additional weeks of suppression alone

Step 3: Options If Endometrium Does NOT Thin Spontaneously

Step 4: Confirm Baseline ≤5 mm, Then Start Estradiol

Day 1 of menstrual bleed (or when baseline confirmed ≤5mm):
- Estradiol valerate (Progynova) 2 mg orally TDS = 6 mg/day
  OR Estradiol valerate 2 mg BD for first 4 days → increase to 6 mg/day

Day 8-10: Monitoring scan
- Target: endometrium ≥7 mm, trilaminar (triple-line) pattern

Day 12-14: Lining check
- If ≥8 mm trilaminar → proceed to progesterone
- If 7-8 mm acceptable → can proceed
- If <7 mm → increase estradiol to 8 mg/day, recheck in 5-7 days

When lining ≥7-8 mm trilaminar + E2 rising:
- Start Micronized Progesterone 400 mg BD vaginally
  OR Progesterone in oil (50 mg IM daily)

Day 5 of progesterone → Transfer Day 5 blastocyst
Day 3 of progesterone → Transfer Day 3 embryo

Special Consideration for This Endometriosis Patient

1. 3D ultrasound or MRI - rule out adenomyosis, submucosal fibroid, intrauterine adhesions (Asherman's)
2. Hysteroscopy - gold standard to directly visualize and treat any intrauterine pathology causing incomplete shedding
3. Endometrial receptivity test (ERA) - if multiple FET failures occur, test for displaced window of implantation (common in endometriosis)

Summary Flow Chart

After Leuprolide withdrawal bleed → Day 2-3 scan
         ↓
Endometrium 8 mm → DO NOT start estradiol
         ↓
Check E2 level
         ↓
E2 low (<50 pg/mL) = suppression confirmed = residual tissue only
         ↓
Wait 7-10 more days → repeat scan
         ↓
Endometrium ≤5 mm?
   YES → Start Estradiol 6 mg/day → monitor → add progesterone → FET
   NO  → Misoprostol 400 mcg vaginally OR norethisterone withdrawal
         → Repeat scan after bleed
         → If still >5mm → Hysteroscopy to evaluate and clear cavity